Grifols, S.A. filings document the formal U.S. reporting record of a Spanish foreign private issuer in plasma-derived medicines. Its 6-K reports include quarterly results releases, earnings presentations, consolidated and individual audited financial statements, and directors' responsibility statements covering financial position, business results, and principal risks and uncertainties.
The filings also disclose Biopharma performance, immunoglobulin, albumin, Alpha-1 and Specialty Proteins trends, regulatory approvals for plasma-related products, and capital-structure actions such as term-loan and revolving-credit refinancing. Inside-information and other-relevant-information notices cover governance, financing, liquidity, leverage, and corporate-structure matters.
Grifols, S.A. has called its Ordinary General Shareholders' Meeting, with first call on June 17, 2026 and the meeting expected to be held on second call on June 18, 2026 at 12:00 p.m. CET at its registered office in Sant Cugat del Vallès, Barcelona.
Shareholders may attend in person or by telematic means, use distance voting and delegation mechanisms, and participate via a Shareholders' Electronic Forum on the corporate website. All shareholders may attend if their shares are registered at least five days before the meeting, but only holders of Class A shares may vote on agenda items. The company details procedures for registration, remote participation, information requests, and privacy, and will provide a free shuttle service on June 18, 2026 between the Sant Joan station and the meeting venue.
Grifols, S.A. has called its Ordinary General Shareholders' Meeting, with first call on June 17, 2026 and the meeting expected to be held on second call on June 18, 2026 at 12:00 p.m. CET at its registered office in Sant Cugat del Vallès, Barcelona.
Shareholders may attend in person or by telematic means, use distance voting and delegation mechanisms, and participate via a Shareholders' Electronic Forum on the corporate website. All shareholders may attend if their shares are registered at least five days before the meeting, but only holders of Class A shares may vote on agenda items. The company details procedures for registration, remote participation, information requests, and privacy, and will provide a free shuttle service on June 18, 2026 between the Sant Joan station and the meeting venue.
Brandes Investment Partners reports beneficial ownership of Grifols Class B shares totaling 27,220,179 ORD and 36,343,419 ADRs, representing 24.31% of the class as of 03/31/2026.
The amendment (Amendment No. 6) to the Schedule 13G/A updates the registrant's holdings and shows shared dispositive power over those shares. The filing is signed by an Executive Director on 05/06/2026.
Brandes Investment Partners reports beneficial ownership of Grifols Class B shares totaling 27,220,179 ORD and 36,343,419 ADRs, representing 24.31% of the class as of 03/31/2026.
The amendment (Amendment No. 6) to the Schedule 13G/A updates the registrant's holdings and shows shared dispositive power over those shares. The filing is signed by an Executive Director on 05/06/2026.
Grifols, S.A. files its Form 20-F annual report for the year ended December 31, 2025, presenting IFRS-IASB financials in millions of euros. Net revenue was €7,524 million versus €7,212 million in 2024, or €7,718 million on a constant-currency basis, reflecting 7.0% growth excluding exchange effects.
Immunoglobulin products remain central, contributing 54.3% of 2025 net revenue. The company highlights high leverage: as of December 31, 2025, current and non-current financial liabilities totaled €9.6 billion, including €9.1 billion of long-term debt, with part of its borrowings at variable interest rates.
The report explains previously disclosed accounting corrections for the Biotek America LLC joint operation and the Shanghai RAAS investment, which adjusted 2022–2023 figures but are now fully incorporated with no additional errors identified in 2025. Extensive risk disclosures cover indebtedness, plasma supply, manufacturing complexity, regulatory compliance, geopolitical tensions, tax changes and the early use of artificial intelligence.
Grifols, S.A. files its Form 20-F annual report for the year ended December 31, 2025, presenting IFRS-IASB financials in millions of euros. Net revenue was €7,524 million versus €7,212 million in 2024, or €7,718 million on a constant-currency basis, reflecting 7.0% growth excluding exchange effects.
Immunoglobulin products remain central, contributing 54.3% of 2025 net revenue. The company highlights high leverage: as of December 31, 2025, current and non-current financial liabilities totaled €9.6 billion, including €9.1 billion of long-term debt, with part of its borrowings at variable interest rates.
The report explains previously disclosed accounting corrections for the Biotek America LLC joint operation and the Shanghai RAAS investment, which adjusted 2022–2023 figures but are now fully incorporated with no additional errors identified in 2025. Extensive risk disclosures cover indebtedness, plasma supply, manufacturing complexity, regulatory compliance, geopolitical tensions, tax changes and the early use of artificial intelligence.
Grifols, S.A. has completed a major refinancing of its 2027 debt, replacing existing borrowings with a new Term Loan B package and revolving credit facility. The new structure includes a USD 2.0 billion dollar term loan, a EUR 1.25 billion euro term loan, and a USD 2.065 billion revolving credit facility.
The term loans mature in seven years and the revolver in six and a half years, extending the company’s debt schedule. Pricing is set at SOFR + 250 basis points for the dollar tranche and Euribor + 300 basis points for the euro tranche, with small original issue discounts and leverage-based margin step-downs. Grifols will use the proceeds to repay its 2019 TLB facilities, redeem remaining 2019 notes, and, together with a separate EUR 500 million notes redemption, lower funded gross debt, reduce cash interest costs, and strengthen its balance sheet while maintaining liquidity.
Grifols, S.A. has completed a major refinancing of its 2027 debt, replacing existing borrowings with a new Term Loan B package and revolving credit facility. The new structure includes a USD 2.0 billion dollar term loan, a EUR 1.25 billion euro term loan, and a USD 2.065 billion revolving credit facility.
The term loans mature in seven years and the revolver in six and a half years, extending the company’s debt schedule. Pricing is set at SOFR + 250 basis points for the dollar tranche and Euribor + 300 basis points for the euro tranche, with small original issue discounts and leverage-based margin step-downs. Grifols will use the proceeds to repay its 2019 TLB facilities, redeem remaining 2019 notes, and, together with a separate EUR 500 million notes redemption, lower funded gross debt, reduce cash interest costs, and strengthen its balance sheet while maintaining liquidity.
Grifols, S.A. reports that its Board of Directors has decided to start a process to evaluate a potential Initial Public Offering in the United States of a portion of the shares of its subsidiary that is the parent of its U.S. Biopharma business. The company stresses that any IPO would depend on regulatory and legal requirements, internal approvals and market conditions, and there is no assurance that it will be undertaken or completed. Grifols also notes that, regardless of whether any IPO occurs, its shares will continue trading in Spain on the mercado continuo, and this communication does not constitute an offer or solicitation to buy or sell securities.
Grifols, S.A. reports that its Board of Directors has decided to start a process to evaluate a potential Initial Public Offering in the United States of a portion of the shares of its subsidiary that is the parent of its U.S. Biopharma business. The company stresses that any IPO would depend on regulatory and legal requirements, internal approvals and market conditions, and there is no assurance that it will be undertaken or completed. Grifols also notes that, regardless of whether any IPO occurs, its shares will continue trading in Spain on the mercado continuo, and this communication does not constitute an offer or solicitation to buy or sell securities.
Grifols, S.A. reported strong FY2025 results, with net revenue of EUR 7,524 million, up 7.0% at constant currency, led by Biopharma and particularly its immunoglobulin franchise. Adjusted EBITDA reached EUR 1,825 million, growing 5.6% at constant currency and 11.9% like-for-like, for a 24.3% margin.
Net profit attributable to the parent more than doubled to EUR 402 million from EUR 157 million in 2024, helped by a higher operating margin and lower financial costs. Free cash flow pre-M&A improved to EUR 468 million, up EUR 201 million, reflecting better working capital, lower interest and normalized capex.
The leverage ratio fell from 4.6x to 4.2x, and all three major rating agencies upgraded or improved outlooks on Grifols’ credit ratings. Management targets 2026 free cash flow pre-M&A pre-dividends of EUR 500–575 million, an Adjusted EBITDA margin of at least 25% with 5–9% constant-currency EBITDA growth, and confirms 2027 goals of leverage at or below 3.5x and cumulative 2024–2027 free cash flow of EUR 1.75–2.0 billion.
Permian Investment Partners and affiliated funds reported beneficial ownership of 18,607,262 Grifols Class B shares, equal to 7.1% of the class. The holdings are spread across several Permian funds and managed accounts, including ADRs and ordinary shares.
The ownership percentages are based on 261,425,110 Class B shares outstanding as of December 31, 2024, as disclosed in Grifols’ Form 20-F. The filers certify the securities were not acquired to change or influence control of Grifols.
Permian Investment Partners and affiliated funds reported beneficial ownership of 18,607,262 Grifols Class B shares, equal to 7.1% of the class. The holdings are spread across several Permian funds and managed accounts, including ADRs and ordinary shares.
The ownership percentages are based on 261,425,110 Class B shares outstanding as of December 31, 2024, as disclosed in Grifols’ Form 20-F. The filers certify the securities were not acquired to change or influence control of Grifols.
Brandes Investment Partners, L.P. has filed an amended Schedule 13G reporting a significant passive ownership position in Grifols SA common shares. The investment adviser reports beneficial ownership of 20.67% of the class, indicating it controls a large block of the company’s equity.
Brandes reports no sole voting or dispositive power over these shares and instead lists only shared dispositive power, meaning decisions to sell or otherwise dispose are made in a shared capacity. The filing also certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Grifols.
Brandes Investment Partners, L.P. has filed an amended Schedule 13G reporting a significant passive ownership position in Grifols SA common shares. The investment adviser reports beneficial ownership of 20.67% of the class, indicating it controls a large block of the company’s equity.
Brandes reports no sole voting or dispositive power over these shares and instead lists only shared dispositive power, meaning decisions to sell or otherwise dispose are made in a shared capacity. The filing also certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Grifols.